Cargando…

Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients

Glioblastoma (GB) is an aggressive type of tumour for which therapeutic options and biomarkers are limited. GB diagnosis mostly relies on symptomatic presentation of the tumour and, in turn, brain imaging and invasive biopsy that can delay its diagnosis. Description of easily accessible and effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Cilibrasi, Chiara, Simon, Thomas, Vintu, Marian, Tolias, Christos, Samuels, Mark, Mazarakis, Nektarios K., Eravci, Murat, Stewart, Nicolas, Critchley, Giles, Giamas, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773644/
https://www.ncbi.nlm.nih.gov/pubmed/35052804
http://dx.doi.org/10.3390/biomedicines10010125
_version_ 1784636143838429184
author Cilibrasi, Chiara
Simon, Thomas
Vintu, Marian
Tolias, Christos
Samuels, Mark
Mazarakis, Nektarios K.
Eravci, Murat
Stewart, Nicolas
Critchley, Giles
Giamas, Georgios
author_facet Cilibrasi, Chiara
Simon, Thomas
Vintu, Marian
Tolias, Christos
Samuels, Mark
Mazarakis, Nektarios K.
Eravci, Murat
Stewart, Nicolas
Critchley, Giles
Giamas, Georgios
author_sort Cilibrasi, Chiara
collection PubMed
description Glioblastoma (GB) is an aggressive type of tumour for which therapeutic options and biomarkers are limited. GB diagnosis mostly relies on symptomatic presentation of the tumour and, in turn, brain imaging and invasive biopsy that can delay its diagnosis. Description of easily accessible and effective biomarkers present in biofluids would thus prove invaluable in GB diagnosis. Extracellular vesicles (EVs) derived from both GB and stromal cells are essential to intercellular crosstalk in the tumour bulk, and circulating EVs have been described as a potential reservoir of GB biomarkers. Therefore, EV-based liquid biopsies have been suggested as a promising tool for GB diagnosis and follow up. To identify GB specific proteins, sEVs were isolated from plasma samples of GB patients as well as healthy volunteers using differential ultracentrifugation, and their content was characterised through mass spectrometry. Our data indicate the presence of an inflammatory biomarker signature comprising members of the complement and regulators of inflammation and coagulation including VWF, FCGBP, C3, PROS1, and SERPINA1. Overall, this study is a step forward in the development of a non-invasive liquid biopsy approach for the identification of valuable biomarkers that could significantly improve GB diagnosis and, consequently, patients’ prognosis and quality of life.
format Online
Article
Text
id pubmed-8773644
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87736442022-01-21 Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients Cilibrasi, Chiara Simon, Thomas Vintu, Marian Tolias, Christos Samuels, Mark Mazarakis, Nektarios K. Eravci, Murat Stewart, Nicolas Critchley, Giles Giamas, Georgios Biomedicines Article Glioblastoma (GB) is an aggressive type of tumour for which therapeutic options and biomarkers are limited. GB diagnosis mostly relies on symptomatic presentation of the tumour and, in turn, brain imaging and invasive biopsy that can delay its diagnosis. Description of easily accessible and effective biomarkers present in biofluids would thus prove invaluable in GB diagnosis. Extracellular vesicles (EVs) derived from both GB and stromal cells are essential to intercellular crosstalk in the tumour bulk, and circulating EVs have been described as a potential reservoir of GB biomarkers. Therefore, EV-based liquid biopsies have been suggested as a promising tool for GB diagnosis and follow up. To identify GB specific proteins, sEVs were isolated from plasma samples of GB patients as well as healthy volunteers using differential ultracentrifugation, and their content was characterised through mass spectrometry. Our data indicate the presence of an inflammatory biomarker signature comprising members of the complement and regulators of inflammation and coagulation including VWF, FCGBP, C3, PROS1, and SERPINA1. Overall, this study is a step forward in the development of a non-invasive liquid biopsy approach for the identification of valuable biomarkers that could significantly improve GB diagnosis and, consequently, patients’ prognosis and quality of life. MDPI 2022-01-07 /pmc/articles/PMC8773644/ /pubmed/35052804 http://dx.doi.org/10.3390/biomedicines10010125 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cilibrasi, Chiara
Simon, Thomas
Vintu, Marian
Tolias, Christos
Samuels, Mark
Mazarakis, Nektarios K.
Eravci, Murat
Stewart, Nicolas
Critchley, Giles
Giamas, Georgios
Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients
title Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients
title_full Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients
title_fullStr Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients
title_full_unstemmed Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients
title_short Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients
title_sort definition of an inflammatory biomarker signature in plasma-derived extracellular vesicles of glioblastoma patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773644/
https://www.ncbi.nlm.nih.gov/pubmed/35052804
http://dx.doi.org/10.3390/biomedicines10010125
work_keys_str_mv AT cilibrasichiara definitionofaninflammatorybiomarkersignatureinplasmaderivedextracellularvesiclesofglioblastomapatients
AT simonthomas definitionofaninflammatorybiomarkersignatureinplasmaderivedextracellularvesiclesofglioblastomapatients
AT vintumarian definitionofaninflammatorybiomarkersignatureinplasmaderivedextracellularvesiclesofglioblastomapatients
AT toliaschristos definitionofaninflammatorybiomarkersignatureinplasmaderivedextracellularvesiclesofglioblastomapatients
AT samuelsmark definitionofaninflammatorybiomarkersignatureinplasmaderivedextracellularvesiclesofglioblastomapatients
AT mazarakisnektariosk definitionofaninflammatorybiomarkersignatureinplasmaderivedextracellularvesiclesofglioblastomapatients
AT eravcimurat definitionofaninflammatorybiomarkersignatureinplasmaderivedextracellularvesiclesofglioblastomapatients
AT stewartnicolas definitionofaninflammatorybiomarkersignatureinplasmaderivedextracellularvesiclesofglioblastomapatients
AT critchleygiles definitionofaninflammatorybiomarkersignatureinplasmaderivedextracellularvesiclesofglioblastomapatients
AT giamasgeorgios definitionofaninflammatorybiomarkersignatureinplasmaderivedextracellularvesiclesofglioblastomapatients